NeoDiagnostix
	Operator of a cancer diagnostics company. The company uses molecular DNA technologies with a substantial portfolio of proprietary biomarkers. The company provides clinicians with a patient\'s molecular profile that provides crucial insights into cancer leading to improved patient care.
	['', 'cancer diagnostics', ' DNA ', 'molecular profile', '']
GenQuest
	Provider of functional genomics screening for cancer therapeutics and diagnostics. The company\'s technology platform currently consists of proprietary methods to discover genes associated with cancer, response to DNA damage, senescence, cellular proliferation and terminal cell differentiation.
	['', 'functional genomics', ' genomics ', 'cancer therapeutics', '']
Diagnoplex
	Developer of non invasive colorectal cancer screening tests. The company develops clinical laboratory kits for screening colorectal cancer, as well as for the detection of colon cancer. It also discovers and optimizes biomarker combinations to detect cancer.
	['', 'cancer screening test', ' ', 'cancer diagnostic', ' ', 'cancer treatment', '']
Jennerex Biotherapeutics
	Developer of oncolytic products for cancer. The company\'s products include JX-594, an engineered oncolytic virus that selectively targets and destroys cancer cells, JX-929 that targets the epidermal growth factor receptor and ras signal transduction pathways and JX-963, which is engineered from a strain of vaccinia virus.
	['', 'cancer treatment', ' ', 'oncolytic product development', ' ', 'vaccinia virus', ' ', 'epidermal growth', '']
Cancer Genetics
	Developer of personalized medicines for cancer diagnostics as well as treatments that are tailored to the specific genetic profile of the individual. The company provides cancer patient management to diagnose, monitor and inform treatment of cancer.
	['', 'cancer diagnostic', ' ', 'cancer treatment', ' ', 'cancer patient management', '']
Mzt Holdings
	Manufacturer & developer of cancer diagnostic technologies and products. The company is a biotechnology company, which engages in the development, manufacture, marketing, distribution, and licensing of cancer diagnostic technologies and products. Its products include NMP22 Test Kit and NMP22 BladderChek Test, which are designed to detect the presence of a specific protein marker in urine correlated with the presence of bladder cancer. Its research and development programs include NMP179 program, a nuclear matrix protein associated with cervical cancer and cervical precancerous conditions; NMP66 program to develop a blood-based test for breast cancer; NMP48 program for prostate cancer; and NMP35, a colon cancer program. In addition, it sells allergy and other diagnostic products manufactured by others. The company sells its products directly to physicians, hospitals, clinics, and physician office laboratories in the United States and Germany, as well as to distributors in other parts of Europe.
	['']
Conforma Therapeutics
	Developer of drugs for the treatment of cancer. The company develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. It offers the HSP90 product, CNF1010 which is used for the treatment of cancer.
	['', 'cancer treatment', ' ', 'tumor cell', ' ', 'cancer growth', '']
Kite Pharma
	Developer of active immunotherapies for cancer. The company has a portfolio of proprietary product candidates designed to stimulate the patient\'s own immune system to fight tumor cells.
	['', 'cancer therapy', ' ', 'cancer immunotherapy', ' ', 'cancer treatment', ' ', 'tumor treatment', '']
Algeta
	Developer of novel targeted therapies for patients with cancer, based on its alpha-pharmaceutical platform. The company is focused to extend and improve cancer patient\'s lives by developing targeted therapies to fulfill unmet medical needs. It\'s lead product Alpharadin is used for treatment for cancer patients with bone metastases. They are also developing thorium targeted conjugates which are based on conjugating the alpha-emitter thorium-227 to tumor-targeting molecules.
	['', 'cancer drug', ' ', 'targeted therapy', ' ', 'bone metastase', '']
Ziopharm
	Developer of drug candidates for cancer treatments. The company operates with the strategy of in-licensing proprietary drug-candidate families with prior ""related-molecule" efficacy in human cancer that could be efficiently and effectively developed and commercialized.
	['', 'cancer therapeutics', ' ', 'molecule therapeutic', ' ', 'healthcare service', '']
Catalyst Oncology
	Provider of information solutions that enable personalized medicine approaches to cancer patient management. The company provides clinical information to physicians, with an emphasis on proprietary testing and also provides diagnostic and prognostic information for individual patients, allowing physicians to create treatment plans that are tailored for each patient\'s needs.
	['', 'medicinal information', ' cancer ', 'patient management', '']
Cell Genesys
	Developer of novel biological therapeutic products for patients with cancer.The company pursues three cancer product platforms -- GVAX(R) cancer vaccines, oncolytic virus therapies and in vivo cancer gene therapies. The company provides clinical trials of GVAX(R) vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma.
	['', 'therapeutic products', ' ', 'cancer treatment', '']
